A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1147 participants.

Also called NCT01618669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking
Phase
Phase 3
Enrolled
  • 1,147 participants (enrolled count) (from the registry)
Sponsor
Astellas Pharma Global Development, Inc. (from the registry)
Registry
  • NCT NCT01618669
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Peru, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01618669. Randomized; no masking. Start 2012-06 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2016-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
Acronym
EXERRT
Intervention (Drug)
Regadenoson
Intervention (Procedure)
Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Lead sponsor
Astellas Pharma Global Development, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01618669
Content hash
ce0c4f7452efdecb16de36eb568282ca33fa72063b6c940f53a9646710ea2bb7